OPTIMISE-CKD drug utilization

Trial Identifier: D169AR00015
Sponsor: AstraZeneca
NCTID:: NCT05932901
Start Date: May 2022
Primary Completion Date: September 2023
Study Completion Date: September 2023
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan, Kyoto Prefecture Kyoto City, Kyoto Prefecture, Japan, 604-0086
Japan, Tokyo Tokyo, Japan, 101-0053
Sweden Uppsala, Sweden, 75322
Sweden Uppsala, Sweden, 75320
United States of America, Minnesota Minnesota, United States of America, 13625